BioWorld

Sep. 12, 2007

Sepracor, GSK Enter $155M Deal Covering Global Lunesta Rights

Sepracor Inc. entered a potential $155 million deal with GlaxoSmithKline plc covering its insomnia product Lunesta in Europe and elsewhere, about six weeks after it filed for European approval of the drug. (BioWorld Today) Read More

ImClone Gains On Erbitux Results; Avastin In Danger?

Enobia Gets $38M In Series B For Enzyme Replacement Trials

Nabi's 'Turnaround' Continues, Sells Biologics Unit For $185M

Aptuit Paying $64M For Evotec Chemistry Unit

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 31, 2026.

Illustration of dopamine signaling in the brain

New schizophrenia targets challenge trial design

BioWorld

The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 28, 2026

AIDS 2026: New targets for metabolic dysfunction despite ART

BioWorld

Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...

Jingxin discloses new muscarinic and sigma receptor agonists

BioWorld Science

Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...